Trial Profile
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Faricimab (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Registrational; Therapeutic Use
- Acronyms YOSEMITE
- Sponsors Chugai Pharmaceutical; Roche
- 19 Jul 2023 According to Genentech Media Release, post-hoc data from the YOSEMITE and RHINE Phase III studies will be presented 2023 American Society of Retina Specialists (ASRS) Annual Meeting, which will be held from July 28 to August 1 in Seattle.
- 01 May 2023 Results of subgroup pooled analysis from two studies (YOSEMITE and RHINE ) assessing efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients published in the Japanese Journal of Ophthalmology.
- 26 Apr 2023 According to Genentech Media Release, post-hoc pooled analysis data from TENAYA and LUCERNE (wet AMD) and YOSEMITE and RHINE (DME) studies were shared in three presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from April 23-27 in New Orleans, LA.